Candel Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

Candel Therapeutics stands at a critical juncture where clinical success meets financial fragility. The data from the aglatimagene Phase 3 trial provides a credible path to market, but the company's high cost of capital and accelerating burn rate create a narrow window for execution. The upcoming 2026 catalyst calendar—including the BLA submission and NSCLC trial launch—will determine if the company can leverage its current liquidity to achieve a sustainable commercial scale. Investors are essentially weighing the probability of FDA approval against the risk of a liquidity crunch. While the RTW deal and the Trinity loan provide necessary bridges, they also introduce liens on intellectual property and restrictive covenants. The ultimate value of the company depends on its ability to convert clinical endpoints into a commercial reality before its cash reserves are exhausted in early 2028.